Weight loss outcomes with FDA-approved medications
Weight loss outcomes with FDA-approved medications
Weight loss reflects results at 72 weeks (tirzepatide), 68 weeks (semaglutide, liraglutide), or 52 weeks (other medications).
FDA: US Food and Drug Administration.
Data from:
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387:205.
Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 2022; 327:138.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384:989.
Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA 2016; 315:2424.
